Inogen (NASDAQ:INGN) vs. SiBone (NASDAQ:SIBN) Head-To-Head Comparison

SiBone (NASDAQ:SIBN) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings for SiBone and Inogen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1	0	5	0	2.67
Inogen	1	1	1	0	2.00

SiBone currently has a consensus price target of $25.00, indicating a potential upside of 47.06%. Inogen has a consensus price target of $11.00, indicating a potential upside of 76.00%. Given Inogen’s higher probable upside, analysts plainly believe Inogen is more favorable than SiBone.

Institutional and Insider Ownership

98.1% of SiBone shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 1.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares SiBone and Inogen”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$193.58 million	3.81	-$30.91 million	($0.51)	-33.33
Inogen	$335.70 million	0.51	-$35.89 million	($1.01)	-6.19

SiBone has higher earnings, but lower revenue than Inogen. SiBone is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

SiBone has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.

Profitability

This table compares SiBone and Inogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-11.24%	-12.86%	-9.43%
Inogen	-7.31%	-13.21%	-8.30%

Summary

SiBone beats Inogen on 8 of the 14 factors compared between the two stocks.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.